Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MBX-8025 + atorvastatin
- Development stage
- Unknown
- Lead developer
- Gilead Sciences
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
MBX-8025 + atorvastatin is a combination of MBX-8025 (seladelpar), a selective peroxisome proliferator-activated receptor delta (PPAR-δ) agonist, and atorvastatin, an HMG-CoA reductase inhibitor (statin). MBX-8025 activates PPAR-δ, leading to improved lipid metabolism, decreased LDL-cholesterol, and beneficial effects on biochemical markers of cholestasis, while atorvastatin lowers cholesterol by inhibiting the rate-limiting step in cholesterol biosynthesis. This combination was studied for synergistic effects on hyperlipidemia, mixed dyslipidemia, insulin resistance, and metabolic syndrome. Clinical trials have demonstrated that the combination reduces apolipoprotein B-100, LDL, triglycerides, non-HDL cholesterol, free fatty acids, high-sensitivity C-reactive protein, and improves several other metabolic endpoints compared to monotherapy.
- Brand names
- seladelpar
- Other names
- MBX-8025 + atorvastatin combination
02
Targets
PPARD (Peroxisome proliferator–activated receptor delta)HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)
Beyond the preview
Go deeper on MBX-8025 + atorvastatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MBX-8025 + atorvastatin.